NIAID Study Finds Eli Lilly's Antibody Drug Unhelpful For Hospitalized COVID-19 Patients

Eli Lilly and Company LLY said Monday that a trial of its antibody treatment for use in hospitalized COVID-19 patients has come to an end as the treatment is unlikely to help such patients. 

What Happened: The one of its kind study — conducted by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health — was evaluating the efficacy of bamlanivimab, according to a statement issued by the company.

Eli Lilly said that trial data has led to the recommendation that the treatment is unlikely to help hospitalized COVID-19 patients recover from an advanced stage of the disease.

Other studies investigating bamlanivimab will continue, including an NIH-sponsored study evaluating the efficacy of the treatment in mild-to-moderate COVID-19 cases and the company’s own Phase 2 trial in people recently diagnosed with COVID-19 in a non-hospitalized setting.

Why It Matters: The Indianapolis, Indiana-based drug giant said it has submitted for an emergency use authorization for bamlanivimab based on its own Phase 2 trial results.

This month, the drugmaker halted the Phase 3 trial of its antibody treatment due to a “potential safety concern.” It was reported earlier that the Eli Lilly plant being readied to make the antibody treatment for COVID-19 was found to have serious quality control problems by the United States Food and Drug Administration.

President Donald Trump was administered a similar antibody treatment from Regeneron Pharmaceuticals Inc REGN, which he touted as a “cure” for COVID-19.

Price Action: Eli Lilly shares closed nearly 0.5% lower at $141.70 on Monday and fell 0.83% in the after-hours session.

Market News and Data brought to you by Benzinga APIs
Posted In: BiotechNewsHealth CareGeneralBamlanivimabCoronavirusCovid-19the National Institute of Allergy and Infectious Diseases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!